Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189-Reference-Cited by-同舟云学术

Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189

Published:2021-07 Issue:7 Volume:32 Page:881-895
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Rodríguez-Abreu D.,Powell S.F.,Hochmair M.J.,Gadgeel S.,Esteban E.,Felip E.,Speranza G.,De Angelis F.,Dómine M.,Cheng S.Y.,Bischoff H.G.,Peled N.,Reck M.,Hui R.,Garon E.B.,Boyer M.,Kurata T.,Yang J.,Pietanza M.C.,Souza F.,Garassino M.C.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference18 articles.

1. KEYTRUDA® (Pembrolizumab). Full Prescribing Information,2020

2. Australian Product Information—KEYTRUDA® (Pembrolizumab). Summary of Product Characteristics,2020

3. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study;Langer;Lancet Oncol,2016

4. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer;Gandhi;N Engl J Med,2018

5. Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer;Gadgeel;J Clin Oncol,2020

Cited by 269 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sleep disturbance as a poor prognostic predictor in patients with advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: A prospective study;Journal of Psychosomatic Research;2024-11

2. An Overview of Immune Checkpoint Inhibitor Toxicities in Bladder Cancer;Toxicology Reports;2024-09

3. Progressive Disease with Mixed Response After Immunotherapy in Non-Small Cell Lung Cancer;Journal of Inflammation Research;2024-09

4. Real-world overview of therapeutic strategies and prognosis of older patients with advanced or metastatic non-small cell lung cancer from the ESME database;Journal of Geriatric Oncology;2024-09

5. Depth of response and treatment outcomes of immune checkpoint inhibitor-based therapy in patients with advanced non-small cell lung cancer and high PD-L1 expression: An exploratory analysis of retrospective multicenter cohort;Investigational New Drugs;2024-08-21